Single-agent venetoclax induces MRD-negative response in relapsed primary plasma cell leukemia with t(11;14)

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61988987%3A17110%2F19%3AA20021Q9" target="_blank" >RIV/61988987:17110/19:A20021Q9 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00843989:_____/19:E0107410

Výsledek na webu

<a href="https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/ajh.25331" target="_blank" >https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/ajh.25331</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1002/ajh.25331" target="_blank" >10.1002/ajh.25331</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Single-agent venetoclax induces MRD-negative response in relapsed primary plasma cell leukemia with t(11;14)

Popis výsledku v původním jazyce

To the Editor: Plasma cell leukemia (PCL) is the most aggressive form of plasma cell dyscrasia. It is characterized by the presence of more than 20% and/or more than 2 × 109 /L of circulating plasma cells (PCs). Primary plasma cell leukemia (pPCL) that presents de novo should be distinguished from secondary PCL, which corresponds to the leukemic transformation of pre-existing multiple myeloma (MM). Primary PCL is characterized by an increased frequency of adverse laboratory and clinical features as well as higher genetic instability than MM. Despite the introduction of novel agents into clinical practice, the prognosis of pPCL remains poor, with an estimated overall survival of 1-2 years in elderly patients and about 3 years in younger patients eligible for stem cell transplantation (SCT).1,2

Název v anglickém jazyce

Single-agent venetoclax induces MRD-negative response in relapsed primary plasma cell leukemia with t(11;14)

Popis výsledku anglicky

To the Editor: Plasma cell leukemia (PCL) is the most aggressive form of plasma cell dyscrasia. It is characterized by the presence of more than 20% and/or more than 2 × 109 /L of circulating plasma cells (PCs). Primary plasma cell leukemia (pPCL) that presents de novo should be distinguished from secondary PCL, which corresponds to the leukemic transformation of pre-existing multiple myeloma (MM). Primary PCL is characterized by an increased frequency of adverse laboratory and clinical features as well as higher genetic instability than MM. Despite the introduction of novel agents into clinical practice, the prognosis of pPCL remains poor, with an estimated overall survival of 1-2 years in elderly patients and about 3 years in younger patients eligible for stem cell transplantation (SCT).1,2

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30205 - Hematology

Projekt

—

Návaznosti

S - Specificky vyzkum na vysokych skolach

Rok uplatnění

2019

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

AMERICAN JOURNAL OF HEMATOLOGY

ISSN

0361-8609

e-ISSN

1096-8652

Svazek periodika

94

Číslo periodika v rámci svazku

1

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

2

Strana od-do

'E35'-'E37'

Kód UT WoS článku

000453909800019

EID výsledku v databázi Scopus

2-s2.0-85057288241